ABSTRACT
The results of HERS do not support the
beneficial effect of HRT in secondary
prevention of CVD.17 This well-designed
randomized, double-blind, placebo-controlled
study evaluated the role of continuous
oestrogen (conjugated equine oestrogen)
plus progestin (medroxyprogesterone acetate)
in preventing recurrent CVD events in
2763 women with documented coronary
disease.